Insulin action during variable hyperglycemic-hyperinsulinemic infusions in hyperandrogenic anovulatory patients and healthy women.
OBJECTIVE
To determine whether 3-month GnRH analogue (GnRH-a) administration to hyperandrogenic anovulatory patients and healthy women affects glucose utilization or endogenous glucose production (EGP) in the postabsorptive state and during variable hyperglycemic-hyperinsulinemic infusions.


METHODS
Prospective, nonrandomized study.


METHODS
Academic research environment.


METHODS
Twelve hyperandrogenic anovulatory patients and 11 healthy women matched by body mass index and waist to hip circumference ratio.


METHODS
Variable hyperglycemic-hyperinsulinemic infusions replicated physiological increases in circulating glucose and insulin levels before and after 3-month GnRH-a administration.


METHODS
Glucose utilization and EGP.


RESULTS
In the postabsorptive state, plasma glucose and insulin levels, glucose utilization, and EGP were similar in hyperandrogenic patients and healthy women. During variable hyperglycemic-hyperinsulinemic infusions, glucose use increased and EGP decreased to similar degrees in both groups of women. Three-month GnRH-a administration to hyperandrogenic patients and healthy women did not affect plasma glucose and insulin levels, glucose utilization and EGP in the postabsorptive state, or glucose utilization and EGP during variable hyperglycemic-hyperinsulinemic infusions.


CONCLUSIONS
Glucose use and EGP in the postabsorptive state and during variable hyperglycemic-hyperinsulinemic infusions are similar in hyperandrogenic anovulatory patients and healthy women of similar body fat distribution and are unaffected by 3-month GnRH-a administration.
Dumesic
D A
DA
Department of OB/GYN, Mayo Clinic, Rochester, Minnesota, USA. ddumesic@mayo.edu
Nielsen
M F
MF
Abbott
D H
DH
Eisner
J R
JR
Nair
K S
KS
Rizza
R A
RA
D000293:Adolescent; D000311:Adrenal Glands / Q000378:metabolism; D000328:Adult; D000858:Anovulation / Q000097:blood* / Q000209:etiology; D001786:Blood Glucose / Q000378:metabolism*; D001823:Body Composition; D002096:C-Peptide / Q000097:blood; D005260:Female; D005934:Glucagon / Q000097:blood; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D017588:Hyperandrogenism / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D007328:Insulin / Q000097:blood* / Q000494:pharmacology*; D007333:Insulin Resistance; D016729:Leuprolide / Q000627:therapeutic use; D008875:Middle Aged; D010053:Ovary / Q000378:metabolism; D011446:Prospective Studies; D013256:Steroids / Q000096:biosynthesis
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D013256:Steroids; D019382:Human Growth Hormone; D005934:Glucagon; D016729:Leuprolide